

CONTRIBUTORS

- Tetsuya Ando, Department of Pharmacology and Therapeutics, Louisiana State University, Shreveport, Louisiana, USA: *Chapter 8*
- Hymie Anisman, Department of Psychology, Carleton University, Ottawa, Ontario, Canada: *Chapter 12*
- Arnaud Aubert, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Chapter 6*
- Ronit Avitsur, Department of Psychology, The Hebrew University, Jerusalem, Israel: *Chapter 16*
- Ohr Barak, Department of Psychology, The Hebrew University, Jerusalem, Israel: *Chapter 16*
- Rose-Marie Bluthé, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Chapter 6*
- Nathalie Castanon, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Chapter 15*
- Edna Cohen, Department of Psychology, The Hebrew University, Jerusalem, Israel: *Chapter 16*
- Sandrine Cremona, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Chapter 6*
- Robert Dantzer, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Preface, Chapter 6, Conclusions and Perspectives*
- Terrence Deak, Department of Psychology, University of Colorado at Boulder, USA: *Chapter 13*
- Adrian J. Dunn, Department of Pharmacology and Therapeutics, Louisiana State University, Shreveport, Louisiana, USA: *Chapter 8*
- Gilles Gheusi, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Chapter 6*
- Michael Irwin, Department of Psychiatry, University of California at San Diego, USA: *Chapter 1*
- Keith W. Kelley, Laboratory of Immunophysiology, University of Illinois at Urbana, USA: *Chapter 6*
- Jan-Peter Konsman, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France: *Chapter 6*

- Sophie Layé, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France:
Chapter 6
- Jacqueline E. Lee, Department of Psychology, University of Colorado at Boulder, USA:
Chapter 10
- Bryan E. Leonard, Department of Pharmacology, National University of Ireland,
Galway, Ireland: *Chapter 14*
- Astrid C. E. Linthorst, Max-Planck Institut für Psychiatrie, Munich, Germany:
Chapter 9
- Michael Maes, University Department of Psychiatry, Anvers, Belgique: *Chapter 2*
- Steven F. Maier, Department of Psychology, University of Colorado at Boulder, USA:
Chapter 10 & 13
- Zul Merali, Department of Psychology, Carleton University, Ottawa, Ontario, Canada:
Chapter 12
- Christina A. Meyers, Department of Neuro-Oncology, University of Texas at Houston,
USA: *Chapter 5*
- Andrew H. Miller, Department of Psychiatry and Behavioral Sciences, Emory Univer-
sity School of Medicine, Atlanta, Georgia, USA: *Chapter 7*
- Erin D. Milligan, Department of Psychology, University of Colorado at Boulder, USA:
Chapter 13
- Avraham Morag, Departement of Psychology, The Hebrew University, Jerusalem,
Israel: *Chapter 16*
- Michel Morag, Department of Psychology, The Hebrew University, Jerusalem, Israel:
Chapter 16
- Pierre Neveu, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France:
Chapter 15
- Kien T. Nguyen, Department of Psychology, University of Colorado at Boulder, USA:
Chapter 10 & 13
- Haim Ovadia, Departement of Psychology, The Hebrew University, Jerusalem, Israel:
Chapter 16
- Carmine M. Pariente, Department of Psychiatry and Behavioral Sciences, Emory Uni-
versity School of Medicine, Atlanta, Georgia, USA: *Chapter 7*
- Patricia Parnet, Integrative Neurobiology, INRA-INSERM U394, Bordeaux, France:
Chapter 6
- Bradley D. Pearce, Department of Psychiatry and Behavioral Sciences, Emory Uni-
versity School of Medicine, Atlanta, Georgia, USA: *Chapter 7*
- Yehuda Pollak, Departement of Psychology, The Hebrew University, Jerusalem, Israel:
Chapter 16
- Avraham Reichenberg, Departement of Psychology, The Hebrew University,
Jerusalem, Israel: *Chapter 16*
- Johannes M. H. M. Reul, Max-Planck Institut für Psychiatrie, Munich, Germany:
Chapter 9
- Lothar Rink, Medizinische Universität zu Lübeck, Germany: *Chapter 3*
- Matthias Rothermundt, Medizinische Universität zu Lübeck, Germany:
Chapter 3
- Eduard D. Schmidt, Department of Pharmacology, Vrije Universiteit, Amsterdam, The
Netherlands: *Chapter 11*
- Andreas Seidel, Medizinische Universität zu Lübeck, Germany: *Chapter 3*
- Yehuda Shavit, Departement of Psychology, The Hebrew University, Jerusalem, Israel:
Chapter 16

Anna Sluzewska,* Department of Adult Psychiatry, University of Medical Sciences, Poznan, Poland: *Chapter 4*

Cai Song, Department of Pharmacology, National University of Ireland, Galway, Ireland: *Chapter 14*

Fred J. H. Tilders, Department of Pharmacology, Vrije Universiteit, Amsterdam, The Netherlands: *Chapter 11*

Ljubisa Vitkovic, CNRS UPR 9023, Montpellier, France: *Conclusions and Perspectives*

Jianping Wan, Department of Pharmacology and Therapeutics, Louisiana State University, Shreveport, Louisiana, USA: *Chapter 8*

Linda R. Watkins, Department of Psychology, University of Colorado at Boulder, USA: *Chapter 10 & 13*

Joseph Weidenfeld, Department of Psychology, The Hebrew University, Jerusalem, Israel: *Chapter 16*

Emmanuelle E. Wollman, CNRS, Paris, France: *Preface, Conclusions and Perspectives*

Raz Yirmiya, Department of Psychology, The Hebrew University, Jerusalem, Israel: *Preface, Chapter 16, Conclusions and Perspectives*

* Deceased.

INDEX

- Acute phase proteins, 4, 5, 26, 27, 50, 53, 60, 63, 110, 201, 239, 256, 272, 323
- Adenosine triphosphate (ATP), 242
- Adrenalectomy, 33, 99–101, 112, 240–243
- Alpha-melanotropic hormone, 243–244, 299–300
- Age, 1, 4, 5, 18, 19, 191, 260
- Alcoholism, 6, 15–16
- Anhedonia, 32, 76, 205–226, 283, 294–296, 299, 317, 319–320
- Anorexia, 9, 10, 32, 49, 80, 85, 93–94, 96–97, 123–124, 205, 292, 299
- Anterior preoptic area: *see* Preoptic area of the hypothalamus, anterior
- Antidepressants: *see* Selective serotonin reuptake inhibitors; Tricyclic antidepressants
- Anxiety, 9, 14–15, 78, 114, 205–226
- Astrocyte, 48, 54
- ATP: *see* Adenosine-triphosphate
- Auto-antibodies, 66–67
- Auto-immune disease: 35, 48, 61, 287–290, 319
- Blood-brain barrier, 48, 53, 54, 87
- Body weight loss, 9, 10, 32, 292
- Cancer, 75–81, 252, 290, 318
- Cholesterol, 28, 29
- Circadian rhythm, 12, 14, 257
- Circumventricular organ, 87, 94–95
- Cognitive disorders, 9, 10, 32, 75–81, 211, 285, 293
- Corticotropin-releasing hormone (CRH), 34, 60, 93–94, 108–109, 113, 117, 118, 130, 142–148, 163, 184–192, 204–205, 297, 325
- CRH: *see* Corticotropin-releasing hormone
- Depression due to a general medical condition, 35, 283–306
- Dexamethasone, 108–109, 111, 112, 164, 297–298
- Dopamine, 34, 117–125, 203–206, 208, 214–215, 218–220, 223–224
- Dysthymia, 201
- Electric shock, 33, 34, 36, 117–118, 120, 180–181, 205, 236–245
- Fatigue, 76, 77, 292–293, 299
- Fatty acids, 28, 36, 38
- Fever, 84, 91, 93, 97, 124, 141, 145, 237–238
- Gender, 1, 3, 4, 6–7, 15, 18, 35–36, 260, 288
- Glucocorticoids: *see* Hypothalamic-pituitary-adrenal axis
- Glucocorticoid feedback, 99–101, 113, 155–156, 298
- Glucocorticoid receptors, 30, 109–114
- Glucocorticoid resistance, 30, 108–114
- Hamilton rating scale for depression, 5, 8, 9, 10, 319
- Helplessness, 34, 76, 236–237, 317, 319–320
- Hippocampus, 30, 91, 132–139, 208, 223–224, 241–242
- Hospitalization, 8, 9, 260
- Hypothalamic-pituitary-adrenal axis, 25, 30, 31, 32, 34, 38, 49, 59, 62, 64–65, 84, 91, 92–93, 108–114, 123, 141, 144–145, 183–192, 204–205, 214, 218, 223–226, 253, 297, 301, 304–305, 321–322
- Hypothalamus, 30, 33, 48, 91, 117–125, 241–242; *See also* Paraventricular nucleus; Preoptic area of the hypothalamus, anterior
- Interferon-alpha (IFN- α), 32, 48, 49, 75–79, 122, 255, 268, 288, 318
- Interferon-gamma (IFN- γ), 27, 30, 34, 35, 37, 48, 52, 271
- Interleukin-1 (IL-1), 27, 29, 30, 33, 34, 36, 37, 48, 49, 51, 59, 84, 91, 96–98, 110–112, 119–121, 135–137, 139, 144, 161–168, 215–222, 235–246, 255, 318, 327
- receptor, 30, 48, 84, 91–92, 97, 101, 166, 167–168
- receptor antagonist, 34, 35, 36, 37, 51, 64, 84, 96–98, 122–123, 135–136, 166–167, 244–245, 324
- Interleukin-2 (IL-2), 11, 12, 27, 29, 30, 34, 36, 48, 49, 52, 77, 110, 121, 135, 139, 210–215, 318
- soluble receptor, 4, 26, 52, 60, 61, 63, 64, 271

- Interleukin-4 (IL-4), 110, 324
- Interleukin-6 (IL-6), 4, 26, 27, 29, 30, 32, 33, 34, 37, 48, 51, 59, 63, 67, 84, 91, 98, 110–112, 121, 123, 144, 271–272, 318, 323
soluble receptor, 4, 51, 63, 323
- Interleukin-10 (IL-10), 34, 35, 37, 52, 271, 324
- Intracranial self-stimulation, 86, 206, 208, 213, 214, 217, 295–296, 319
- In vivo microdialysis, 131–132, 210, 220–221
- Iron, 29
- Lipopolysaccharide (LPS), 32, 33, 91, 96–98, 118–119, 132–134, 137–139, 141–142, 144, 154, 205, 207–210, 268–269, 292–305
- Lymphocyte proliferation, 1, 3, 4, 6, 7, 8, 15, 17, 34, 49, 61, 144, 255, 260, 269–270, 322
- Lymphocyte subsets, 2, 3, 12, 18, 270
- Lymphokine-activated killer cell activity, 11, 13
- Macrophage, 33, 48, 255
- Major depression, 14, 32, 33, 38, 59, 63–68, 108–110, 142, 201, 271
- Melancholia, 9, 201, 291, 327
- Meta-analysis, 1, 2, 4, 5, 9, 25
- Microglia, 48, 53, 54, 255
- Monocyte, 2, 25, 34, 50, 51, 60
- Motivation, 85–87, 201
- Natural killer (NK) cell, 1, 3, 6, 7, 8, 10, 11, 12, 15, 16, 17, 20, 49, 50, 260, 270, 322
- Neuropsychology, 75–79
- Neurotoxicity, 77
- Neutrophil, 25
- Nitric oxide, 92, 94, 239–240, 304
- Noradrenaline, 34, 117–125, 137–139, 141, 203, 205, 208–209, 214–215, 218–220, 223–226, 304–305
- Novelty, 181, 205, 211, 221
- Nucleus accumbens, 214, 218, 220, 223–224
- Nucleus tractus solitarius, 94–95, 118, 140, 241, 243, 246
- Olfactory bulbectomy, 26, 36, 65
- Pain, 293, 299
- Panic disorder, 15
- Paraventricular nucleus, 120, 123, 139, 184–186, 208, 223–224
- Physical exercise, 154, 157–158, 159–160
- Preoptic area of the hypothalamus, anterior, 137–141
- Prostaglandins, 25, 26, 52, 60, 61, 87, 94, 134–135, 260
- Psychomotor retardation, 9, 32, 49, 76, 292–293, 298
- Psychosocial stressors, 5, 7, 20, 33, 35, 38, 67, 158, 160, 259
- Restraint, 33, 100, 118, 154, 157, 159, 160, 237, 245
- Selective serotonin reuptake inhibitors (SSRI), 36, 37, 38, 51, 79, 80, 113, 273–277, 300–305, 323–324
- Sensitization, 177–192, 205, 223–226
- Serotonin, 25, 30, 31, 34, 37, 61, 66–67, 117–125, 132–137, 141–142, 145, 203–205, 214–215, 218–220, 223–225, 259, 304–305, 325
- Sexual behaviour, 296
- Sickness behaviour, 32, 60, 83–102, 110, 130, 141–142, 145–148, 200–201, 221, 235–236, 283, 291, 301–302, 317
- Sleep disorders, 6, 9, 10–14, 32, 49, 292, 322
- Smoking, 5, 6, 16–17
- Social exploration, 32, 85, 96, 293
- Spatial learning, 211–212, 293
- Stress: *see* Electric shock; Psychosocial stressors; Restraint
- Stressor controllability, 237, 245
- Substance P, 154–156, 159
- Sympathetic nervous system, 155–156, 181, 253
- Th1/Th2 balance, 52, 257
- Thyroid gland, 30, 31, 32, 38
- Treatment-resistant depression, 62–68
- Tricyclic antidepressants, 36, 37, 38, 51, 52, 62, 79, 80, 113, 269, 273–277, 300–305, 323–324
- Tryptophan, 31, 32, 118–122, 325–326
- Tumor necrosis factor-alpha (TNF- α), 30, 34, 48, 59, 84, 91, 122, 135, 137, 144, 222–226, 304, 318, 327
- Vagus nerve, 89–91
- Vasopressin, 98–99, 184–189, 205, 299–300
- Viral infection, 18, 20, 35, 48, 67–68, 109, 118, 254–255, 268, 285, 289, 291, 299, 322
- White blood cells, 5, 16, 25, 255
- Whole blood assay of cytokines, 37, 50, 323